Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

NCT05563844 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma，DLBCL

Interventions

DRUG: PM 8.4 mg/m^2
DRUG: PM 11.2 mg/m^2

Sponsor

Chengdu Zenitar Biomedical Technology Co., Ltd